SPECIAL REPORT
- Food Network, HGTV Drive Scripps Networks' Upside Surprise
- Tommy Lee, Medical Tourism and Nasty Santa, Your Emails
- U.S. Markets Gain 3% for the Week Despite 10.2% Unemployment
- Disney's 'Carol' Tests Widest 3-D Release Ever
- Stimulus II? Jobs Tax Credit=Cash For Clunkers
- Rockwell Automation Earnings: What Options Are Saying
- Gold Will Touch Higher Lows and Higher Highs: Analyst
- Is Misery Alive And Well in Your Office?
- Consumers Haven't Changed, They Are Just Pickier
- Sweeping Health Care Overhaul Bill Passes House
- For the Jobless, 10% is Harder Than Before
- Week Ahead: Stocks Search for Catalyst in Quiet Week
- Outlook: Dollar Likely to Ride Higher on Bleak Jobs Report
- Geithner: More Stimulus, Not a Bank Tax
- Windfall is Seen as Bank Bonuses are Paid in Stock
- Buffett's Berkshire Hathaway Says Net Income Tripled
- Cramer: Earnings, IPOs Dominate Next Week
- Buying Fear: How to Own Volatility
RSS FEED
Pharma's Market
![]() |
DNDN says it will use the money to "fund our commercialization activities for Provenge," among other things. Provenge is a therapeutic vaccine for prostate cancer that is in the middle of a crucial clinical trial.
Back in February I blogged about Morgan Stanley and a hedge fund, Visium Asset Management, taking a combined 16.5 percent stake in DNDN. Big investors like that have 45 days to disclose their positions to the Securities and Exchange Commission, so the identity of Dendreon's secret lover could be revealed in the not-too-distant future.
Dendreon can be a very volatile stock. It has a huge short interest or shares that belong to investors who are hoping the price will fall. This is not an investment for the faint of heart. But obviously another one of the "big boys" has a strong ticker.
Questions? Comments?










